ArticleFrontiers in immunology2025

Response to dabrafenib and trametinib combined with pembrolizumab in an elderly patient with lung adenocarcinoma of unknown primary harboring BRAF V600E mutation and high PD-L1 expression: a case report.

Nan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.